SHREVEPORT, La. -- Patients who have a condition called giant cell arteritis are concerned it could be going undiagnosed. Dr. Robert Goodman of The Arthritis and Rheumatology Clinic in Shreveport ...

SHREVEPORT, La. - Giant cell arteritis, also known as temporal arteritis, is a less common condition where people get inflammation of the arteries that go to the head and neck. Symptoms include, head ...

For patients with giant cell arteritis (GCA), a higher total vascular score (TVS) based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at diagnosis is associated with a ...

Exposure to environmental particulate matter ≤ 10 μm in diameter (PM 10) is associated with an increased risk for giant cell arteritis, particularly in older individuals aged ≥ 70 years and those with ...

Please provide your email address to receive an email when new articles are posted on . Although it is known that the selective Janus kinase (JAK) inhibitor upadacitinib (Rinvoq, AbbVie) blocks the ...

Recent advances in the study of inflammatory vasculitides have underscored the complexity of both giant cell arteritis (GCA) and Takayasu arteritis (TAK). Research has increasingly revealed the ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Senescence ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. A substantial proportion of patients who received ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window One-third of ...

Findings showed 46% of patients who received upadacitinib 15mg achieved sustained remission at week 52 compared with 29% of patients who received placebo. Patients with giant cell arteritis (GCA) who ...

(RTTNews) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adults with giant ...

Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. Overall, 82 patients (average age, 73 years; 60% ...